ClinicalTrials.gg
CompletedNCT00972504Updated Aug 2, 2017Results posted

723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover

A Phase 2 interventional study of GSK835726 10mg and GSK1004723 1000mcg in Rhinitis, Allergic, Seasonal, sponsored by GlaxoSmithKline. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-02.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Seasonal · GlaxoSmithKline.

Enrollment
18th of 26
54 · median 68
Started
2009
the only one that year
Phase 2
7 of 31
none open now
Registered
24th of 31
by date

Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, this one is the 18th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2009, is one of 7 in phase 2, and was the 24th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline as a file.
02

Study summary

This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.

03

Conditions studied

  • Rhinitis, Allergic, Seasonal

Keywords

  • Proof of concept
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is healthy apart from seasonal allergic rhinitis, as determined by a physician. Can have mild asthma.
  • Males or female using
  • Aged 18 - 65
  • Weight 50kg+, 19-32 kg/m2
  • Exhibit response to Challenge Chamber and skin prick test.
  • Non-smoker
  • Capable of giving
  • and ALT\<2xULN; alkaline phosphatase and \<or=1.5xULN

Exclusion criteria

Exclusion Criteria:

  • No nasal structural abnornmality/polyposis, surgery, infection.
  • any respiratory disease, other than mild asthma or seasonal allergic rhinitis
  • participated in another clinical study within 30 days.
  • Subject has donated a unit of blood within 1 month
  • Use of prescription or non-prescription drugs, including vitamins and st john's wort within 7 days of trial.
  • History of sensitivty to drug
  • History of alcohol/drug abuse within 12 months.
  • Positive antibody test
  • Positive antibody test
  • Risk of non-compliance with study protocol
  • Pregnant or llactating females
  • Perenial allergic rhinitis
  • Administration of oral, injectable or dermal corticosteriods within 8 weeks, intranasal or inhaled within 3 weeks.
  • Past or present disease that may affect outcome, as judge by investigator
  • Specific Immunotherapy within 2 years
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    GSK835726 (10mg)

    10mg oral dose

    Drug: GSK835726 10mg

  • Active comparator
    GSK1004723 (1000mcg)

    1000mcg nasal spray solution

    Drug: GSK1004723 1000mcg

  • Active comparator
    Cetirizine 10mg

    10mg cetirizine as active comparator

    Drug: Cetirizine 10mg

  • Placebo comparator
    placebo

    placebo

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

    On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.

    Time frame: Day 3 of each treatment period (approximately up to 63 days)

Secondary outcomes

  1. Weighted Mean of the Individual Components of TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

    On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed to produce the TNSS at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.

    Time frame: Day 3 of each treatment period (approximately up to 63 days)

  2. Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

    On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Wet tissue weight assessments was measured as a surrogate marker of nasal secretion at 60, 120, 180, 240, 300 and 360 minutes. The adjusted mean is provided as least square mean.

    Time frame: Day 3 of each treatment period (approximately up to 63 days)

  3. Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

    On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal congestion was measured on 0-10 centimeter VAS scale (0: no symptoms and 10: the worst possible symptoms) with low score indicates well-being and higher values indicate greater congestion. It was measured at 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes. The adjusted mean is provided as least square mean.

    Time frame: Day 3 of each treatment period (approximately up to 63 days)

  4. Mean Forced Expiratory Volume in 1 Second (FEV1)

    On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. FEV1 was measured at pre-challenge, 60, 120, 180, 240, 300 and 360 minutes.

    Time frame: Day 3 of each treatment period (approximately up to 63 days)

  5. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or is associated with liver injury and impaired liver function defined as: alanine aminotransferase \>=3 times upper limit of normal (ULN), and total bilirubin \>=2 times ULN or international normalized ratio more than 1.5.

    Time frame: approximately up to 63 days

07

Results

Posted Aug 2, 2017

Participant flow

From June-2009 to August-2009, total of 54 participants were randomized at one site in Germany.

Participant flow — Overall Study
MilestoneOverall Study
Started54
Completed51
Not completed3
Withdrew: Adverse event2
Withdrew: Investigator discretion1

Outcome measures

PrimaryWeighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.

Time frame:
Day 3 of each treatment period (approximately up to 63 days)
Reported as:
Least squares mean · Score on a scale
Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
Score on a scalePlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 34.9 (4.4 to 5.4)4.2 (3.7 to 4.8)3.6 (3.1 to 4.1)3.5 (3.0 to 4.1)
Statistical analysis
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): -0.7 · 95% CI -1.2 to -0.1
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -1.3 · 95% CI -1.8 to -0.8
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -1.4 · 95% CI -1.9 to -0.8
SecondaryWeighted Mean of the Individual Components of TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed to produce the TNSS at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean.

Time frame:
Day 3 of each treatment period (approximately up to 63 days)
Reported as:
Least squares mean · Score on a scale
Weighted Mean of the Individual Components of TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
Score on a scalePlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Nasal Blockage1.5 (1.3 to 1.7)1.7 (1.5 to 1.8)1.3 (1.1 to 1.4)1.3 (1.1 to 1.4)
Rhinorrhoea1.5 (1.3 to 1.7)1.3 (1.1 to 1.4)1.1 (0.9 to 1.3)1.0 (0.9 to 1.2)
Nasal Itching1.1 (0.9 to 1.3)0.9 (0.7 to 1.0)0.8 (0.6 to 1.0)0.8 (0.6 to 1.0)
Sneezing0.8 (0.7 to 0.9)0.4 (0.3 to 0.6)0.5 (0.4 to 0.6)0.5 (0.3 to 0.6)
Statistical analysis
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): 0.1 · 95% CI -0.0 to 0.3Comparison of Nasal Blockage between Placebo and GSK1004723 1000 µg once daily.
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -0.2 · 95% CI -0.4 to -0.1Comparison of Nasal Blockage between Placebo and GSK835726 10 mg once daily.
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -0.2 · 95% CI -0.4 to -0.1Comparison of Nasal Blockage between Placebo and Cetirizine 10 mg once daily.
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): -0.2 · 95% CI -0.4 to -0.1Comparison of Rhinorrhoea between Placebo and GSK1004723 1000 µg once daily.
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.2Comparison of Rhinorrhoea between Placebo and GSK835726 10 mg once daily.
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -0.5 · 95% CI -0.6 to -0.3Comparison of Rhinorrhoea between Placebo and Cetirizine 10 mg once daily.
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): -0.2 · 95% CI -0.4 to -0.1Comparison of Nasal Itching between Placebo and GSK1004723 1000 µg once daily.
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -0.3 · 95% CI -0.5 to -0.2Comparison of Nasal Itching between Placebo and GSK835726 10 mg once daily.
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -0.3 · 95% CI -0.5 to -0.2Comparison of Nasal Itching between Placebo and Cetirizine 10 mg once daily.
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): -0.3 · 95% CI -0.5 to -0.2Comparison of Sneezing between Placebo and GSK1004723 1000 µg once daily.
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -0.3 · 95% CI -0.4 to -0.2Comparison of Sneezing between Placebo and GSK835726 10mg once daily.
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -0.3 · 95% CI -0.5 to -0.2Comparison of Sneezing between Placebo and Cetirizine 10mg once daily.
SecondaryWeighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Wet tissue weight assessments was measured as a surrogate marker of nasal secretion at 60, 120, 180, 240, 300 and 360 minutes. The adjusted mean is provided as least square mean.

Time frame:
Day 3 of each treatment period (approximately up to 63 days)
Reported as:
Least squares mean · Grams
Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
GramsPlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 36.251 (5.198 to 7.304)5.210 (4.167 to 6.254)4.491 (3.446 to 5.536)3.459 (2.406 to 4.512)
Statistical analysis
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): -1.041 · 95% CI -1.870 to -0.212
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -1.760 · 95% CI -2.584 to -0.936
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -2.792 · 95% CI -3.626 to -1.957
SecondaryWeighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal congestion was measured on 0-10 centimeter VAS scale (0: no symptoms and 10: the worst possible symptoms) with low score indicates well-being and higher values indicate greater congestion. It was measured at 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes. The adjusted mean is provided as least square mean.

Time frame:
Day 3 of each treatment period (approximately up to 63 days)
Reported as:
Least squares mean · Score on a scale
Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3
Score on a scalePlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 33.97 (3.36 to 4.57)4.29 (3.69 to 4.89)2.92 (2.32 to 3.52)2.90 (2.29 to 3.51)
Statistical analysis
  • Placebo vs GSK1004723 1000 µg Once Daily · Mean difference (final values): 0.32 · 95% CI -0.28 to 0.93
  • Placebo vs GSK835726 10 mg Once Daily · Mean difference (final values): -1.05 · 95% CI -1.65 to -0.45
  • Placebo vs Cetirizine 10 mg Once Daily · Mean difference (final values): -1.07 · 95% CI -1.68 to -0.46
SecondaryMean Forced Expiratory Volume in 1 Second (FEV1)

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. FEV1 was measured at pre-challenge, 60, 120, 180, 240, 300 and 360 minutes.

Time frame:
Day 3 of each treatment period (approximately up to 63 days)
Reported as:
Mean · Liters
Mean Forced Expiratory Volume in 1 Second (FEV1)
LitersPlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
FEV1-Pre challenge3.908 ± 0.70513.935 ± 0.65153.924 ± 0.70553.932 ± 0.6654
FEV1,1 hour3.949 ± 0.73193.959 ± 0.68043.948 ± 0.71253.958 ± 0.6865
FEV1,2 hour3.910 ± 0.71613.948 ± 0.64443.936 ± 0.70143.925 ± 0.6829
FEV1,3 hour3.901 ± 0.71343.938 ± 0.67743.918 ± 0.69413.899 ± 0.7179
FEV1,4 hour3.881 ± 0.73643.913 ± 0.70833.903 ± 0.70673.903 ± 0.7124
FEV1,5 hour3.858 ± 0.73143.890 ± 0.68683.890 ± 0.69543.858 ± 0.7406
FEV1,6 hour3.914 ± 0.70993.877 ± 0.63813.887 ± 0.68943.868 ± 0.7231
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or is associated with liver injury and impaired liver function defined as: alanine aminotransferase \>=3 times upper limit of normal (ULN), and total bilirubin \>=2 times ULN or international normalized ratio more than 1.5.

Time frame:
approximately up to 63 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsPlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Any AE15531317
Any SAE0000

Adverse events

Collected over AEs and SAEs were reported throughout the study (approximately up to 63 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/52 (0%)0/52 (0%)15/52 (28.8%)
GSK1004723 1000 µg Once Daily0/54 (0%)0/54 (0%)53/54 (98.1%)
GSK835726 10 mg Once Daily0/53 (0%)0/53 (0%)13/53 (24.5%)
Cetirizine 10 mg Once Daily0/52 (0%)0/52 (0%)17/52 (32.7%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboGSK1004723 1000 µg Once DailyGSK835726 10 mg Once DailyCetirizine 10 mg Once Daily
Nasal discomfortRespiratory, thoracic and mediastinal disorders1/5247/541/531/52
HeadacheNervous system disorders8/527/546/5311/52
Lacrimation increasedEye disorders0/525/540/530/52
FatigueGeneral disorders2/524/543/534/52
Nasal congestionRespiratory, thoracic and mediastinal disorders1/524/540/531/52
Nasal drynessRespiratory, thoracic and mediastinal disorders2/524/540/530/52
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/523/540/530/52
SneezingRespiratory, thoracic and mediastinal disorders0/523/540/530/52
EpistaxisRespiratory, thoracic and mediastinal disorders1/521/540/532/52
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/521/541/532/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study
Mean37.9 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female15
Male39
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
White - White/Caucasian/European Heritage54
08

Study locations

1 site
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
09

References and documents

Publications

  • Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84-98. doi: 10.1159/000329738. Epub 2011 Dec 29. PubMed 22212854 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 8 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2009
First posted
Sep 7, 2009
Start
Jun 1, 2009
Primary completionActual
Aug 1, 2009
CompletionActual
Aug 14, 2009
Results first posted
Aug 2, 2017
Last update
Aug 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00972504
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 7, 2009
Start date
Jun 1, 2009
Primary completion
Aug 1, 2009
Completion
Aug 14, 2009
Results posted
Aug 2, 2017
Last update
Aug 2, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK 835726 · GSK 1004723 · Cetirizine

Start the discussion